Ghost Tree Capital, LLC historic quarter change: USA Stocks, Reduced
In share positions in stocks (listed in the US), over 14 quarters from 2013-12-31 to 2024-09-30, Ghost Tree Capital, LLC opened 144 positions, added to 89, reduced 77 and sold out of 127.
- Q3 2024: Stock MLTX; Country of operation Switzerland; Class CLASS A ORD; Shares before 300,000.
- Q3 2024: Stock VRDN; Country of operation United States; Class COM; Shares before 587,708.
- Q3 2024: Stock SLNO; Country of operation United States; Class COM; Shares before 300,000.
- Q3 2024: Stock CRBP; Country of operation United States; Class COM NEW; Shares before 175,000.
Each consecutive pair of Form 13F-HR filings compared (SEC CIK 1595851), 14 quarters: Q3 2024 (2024-06-30 to 2024-09-30, filed 2024-11-14); Q2 2024 (2024-03-31 to 2024-06-30, filed 2024-08-14); Q1 2024 (2023-12-31 to 2024-03-31, filed 2024-05-15); Q3 2016 (2016-06-30 to 2016-09-30, filed 2016-11-14); Q2 2016 (2016-03-31 to 2016-06-30, filed 2016-08-12); Q1 2016 (2015-12-31 to 2016-03-31, filed 2016-05-16); Q4 2015 (2015-09-30 to 2015-12-31, filed 2016-02-17); Q3 2015 (2015-06-30 to 2015-09-30, filed 2015-11-16); Q2 2015 (2015-03-31 to 2015-06-30, filed 2015-09-09); Q1 2015 (2014-12-31 to 2015-03-31, filed 2015-05-15); Q4 2014 (2014-09-30 to 2014-12-31, filed 2015-02-18); Q3 2014 (2014-06-30 to 2014-09-30, filed 2014-11-14); Q2 2014 (2014-03-31 to 2014-06-30, filed 2014-08-14); Q1 2014 (2013-12-31 to 2014-03-31, filed 2014-05-15). Rows for the same security, class and put/call are added together. Value change is the filed value at each quarter end, so it includes the price move. Only the filings held here are compared; the firm's 13F-HR filings go back to the quarter ended 2013-12-31. Not compared, as a quarter between them is not held here yet: 2016-09-30 to 2023-12-31 (missing 2016-12-31, 2017-03-31, 2017-06-30, 2017-09-30, 2017-12-31, 2018-03-31, 2018-06-30, 2018-09-30, 2018-12-31, 2019-03-31, 2019-06-30, 2019-09-30, 2019-12-31, 2020-03-31, 2020-06-30, 2020-09-30, 2020-12-31, 2021-03-31, 2021-06-30, 2021-09-30, 2021-12-31, 2022-03-31, 2022-06-30, 2022-09-30, 2022-12-31, 2023-03-31, 2023-06-30, 2023-09-30).
| Quarter | Stock | Country of operation | Class | Shares before | Shares after | Share change | Value before | Value after | Value change | Filed |
|---|
| Q3 2024 | MLTX
MOONLAKE IMMUNOTHERAPEUTICS | Switzerland | CLASS A ORD | 300,000 | 128,411 | -171,589 | $13,191,000 | $6,474,483 | -$6,716,517 | 2024-11-14 |
|---|
| Q3 2024 | VRDN
VIRIDIAN THERAPEUTICS INC | United States | COM | 587,708 | 75,000 | -512,708 | $7,646,081 | $1,706,250 | -$5,939,831 | 2024-11-14 |
|---|
| Q3 2024 | SLNO
SOLENO THERAPEUTICS INC | United States | COM | 300,000 | 150,000 | -150,000 | $12,240,000 | $7,573,500 | -$4,666,500 | 2024-11-14 |
|---|
| Q3 2024 | CRBP
CORBUS PHARMACEUTICALS HLDGS | United States | COM NEW | 175,000 | 160,000 | -15,000 | $7,918,750 | $3,300,800 | -$4,617,950 | 2024-11-14 |
|---|
| Q3 2024 | SYRE
SPYRE THERAPEUTICS INC | United States | COM NEW | 250,237 | 60,000 | -190,237 | $5,883,072 | $1,764,600 | -$4,118,472 | 2024-11-14 |
|---|
| Q3 2024 | APLS
APELLIS PHARMACEUTICALS INC | United States | COM | 135,000 | 65,000 | -70,000 | $5,178,600 | $1,874,600 | -$3,304,000 | 2024-11-14 |
|---|
| Q3 2024 | CRNX
CRINETICS PHARMACEUTICALS IN | United States | COM | 240,000 | 150,000 | -90,000 | $10,749,600 | $7,665,000 | -$3,084,600 | 2024-11-14 |
|---|
| Q3 2024 | PCVX
VAXCYTE INC | United States | COM | 150,000 | 80,000 | -70,000 | $11,326,500 | $9,141,600 | -$2,184,900 | 2024-11-14 |
|---|
| Q3 2024 | TGTX
TG THERAPEUTICS INC | United States | COM | 500,000 | 310,000 | -190,000 | $8,895,000 | $7,250,900 | -$1,644,100 | 2024-11-14 |
|---|
| Q3 2024 | ROIV
ROIVANT SCIENCES LTD | | SHS | 1,000,000 | 800,000 | -200,000 | $10,570,000 | $9,232,000 | -$1,338,000 | 2024-11-14 |
|---|
| Q3 2024 | CGON
CG ONCOLOGY INC | United States | COM | 260,000 | 250,000 | -10,000 | $8,208,200 | $9,432,500 | +$1,224,300 | 2024-11-14 |
|---|
| Q3 2024 | SVRA
SAVARA INC | United States | COM | 1,050,876 | 725,000 | -325,876 | $4,235,030 | $3,074,000 | -$1,161,030 | 2024-11-14 |
|---|
| Q3 2024 | CATX
PERSPECTIVE THERAPEUTICS INC | United States | COM NEW | 925,000 | 750,000 | -175,000 | $9,222,250 | $10,012,500 | +$790,250 | 2024-11-14 |
|---|
| Q3 2024 | IMVT
IMMUNOVANT INC | United States | COM | 260,000 | 215,000 | -45,000 | $6,864,000 | $6,129,650 | -$734,350 | 2024-11-14 |
|---|
| Q3 2024 | RYTM
RHYTHM PHARMACEUTICALS INC | United States | COM | 117,388 | 78,842 | -38,546 | $4,819,951 | $4,130,532 | -$689,419 | 2024-11-14 |
|---|
| Q3 2024 | PHAT
PHATHOM PHARMACEUTICALS INC | United States | COM | 600,000 | 375,000 | -225,000 | $6,180,000 | $6,780,000 | +$600,000 | 2024-11-14 |
|---|
| Q3 2024 | NGNE
NEUROGENE INC | | COM | 70,000 | 50,000 | -20,000 | $2,547,300 | $2,098,000 | -$449,300 | 2024-11-14 |
|---|
| Q3 2024 | OLMA
OLEMA PHARMACEUTICALS INC | United States | COM | 550,000 | 535,000 | -15,000 | $5,951,000 | $6,387,900 | +$436,900 | 2024-11-14 |
|---|
| Q3 2024 | PRQR
PROQR THRAPEUTICS N V | | SHS EURO | 900,000 | 887,700 | -12,300 | $1,494,000 | $1,615,614 | +$121,614 | 2024-11-14 |
|---|
| Q3 2024 | AXSM
AXSOME THERAPEUTICS INC | United States | COM | 150,000 | 135,000 | -15,000 | $12,075,000 | $12,132,450 | +$57,450 | 2024-11-14 |
|---|
| Q2 2024 | SRPT
SAREPTA THERAPEUTICS INC | United States | COM | 125,000 | 55,000 | -70,000 | $16,182,500 | $8,690,000 | -$7,492,500 | 2024-08-14 |
|---|
| Q2 2024 | AXSM
AXSOME THERAPEUTICS INC | United States | COM | 210,000 | 150,000 | -60,000 | $16,758,000 | $12,075,000 | -$4,683,000 | 2024-08-14 |
|---|
| Q2 2024 | TARS
TARSUS PHARMACEUTICALS INC | United States | COM | 300,000 | 235,000 | -65,000 | $10,905,000 | $6,387,300 | -$4,517,700 | 2024-08-14 |
|---|
| Q2 2024 | SVRA
SAVARA INC | United States | COM | 1,600,000 | 1,050,876 | -549,124 | $7,968,000 | $4,235,030 | -$3,732,970 | 2024-08-14 |
|---|
| Q2 2024 | TGTX
TG THERAPEUTICS INC | United States | COM | 825,000 | 500,000 | -325,000 | $12,548,250 | $8,895,000 | -$3,653,250 | 2024-08-14 |
|---|
| Q2 2024 | CABA
CABALETTA BIO INC | United States | COM | 375,000 | 370,899 | -4,101 | $6,397,500 | $2,774,325 | -$3,623,175 | 2024-08-14 |
|---|
| Q2 2024 | ALNY
ALNYLAM PHARMACEUTICALS INC | United States | COM | 60,000 | 22,500 | -37,500 | $8,967,000 | $5,467,500 | -$3,499,500 | 2024-08-14 |
|---|
| Q2 2024 | VRDN
VIRIDIAN THERAPEUTICS INC | United States | COM | 625,000 | 587,708 | -37,292 | $10,943,750 | $7,646,081 | -$3,297,669 | 2024-08-14 |
|---|
| Q2 2024 | ROIV
ROIVANT SCIENCES LTD | | SHS | 1,300,000 | 1,000,000 | -300,000 | $13,702,000 | $10,570,000 | -$3,132,000 | 2024-08-14 |
|---|
| Q2 2024 | BBIO
BRIDGEBIO PHARMA INC | United States | COM | 175,000 | 140,000 | -35,000 | $5,411,000 | $3,546,200 | -$1,864,800 | 2024-08-14 |
|---|
| Q2 2024 | REPL
REPLIMUNE GROUP INC | United States | COM | 650,000 | 450,000 | -200,000 | $5,310,500 | $4,050,000 | -$1,260,500 | 2024-08-14 |
|---|
| Q2 2024 | CTMX
CYTOMX THERAPEUTICS INC | United States | COM | 600,000 | 300,000 | -300,000 | $1,308,000 | $366,000 | -$942,000 | 2024-08-14 |
|---|
| Q2 2024 | KRYS
KRYSTAL BIOTECH INC | United States | COM | 14,000 | 8,500 | -5,500 | $2,491,020 | $1,560,940 | -$930,080 | 2024-08-14 |
|---|
| Q2 2024 | RYTM
RHYTHM PHARMACEUTICALS INC | United States | COM | 125,000 | 117,388 | -7,612 | $5,416,250 | $4,819,951 | -$596,299 | 2024-08-14 |
|---|
| Q2 2024 | PMVP
PMV PHARMACEUTICALS INC | United States | COM | 675,000 | 375,000 | -300,000 | $1,147,500 | $607,500 | -$540,000 | 2024-08-14 |
|---|
| Q2 2024 | INSM
INSMED INC | United States | COM PAR $.01 | 150,000 | 65,000 | -85,000 | $4,069,500 | $4,355,000 | +$285,500 | 2024-08-14 |
|---|
| Q1 2024 | KRYS
KRYSTAL BIOTECH INC | United States | COM | 50,000 | 14,000 | -36,000 | $6,203,000 | $2,491,020 | -$3,711,980 | 2024-05-15 |
|---|
| Q1 2024 | EYPT
EYEPOINT PHARMACEUTICALS INC | United States | COM NEW | 165,000 | 90,000 | -75,000 | $3,813,150 | $1,860,300 | -$1,952,850 | 2024-05-15 |
|---|
| Q1 2024 | MDGL
MADRIGAL PHARMACEUTICALS INC | United States | COM | 15,000 | 6,500 | -8,500 | $3,470,700 | $1,735,760 | -$1,734,940 | 2024-05-15 |
|---|
| Q1 2024 | PMVP
PMV PHARMACEUTICALS INC | United States | COM | 725,000 | 675,000 | -50,000 | $2,247,500 | $1,147,500 | -$1,100,000 | 2024-05-15 |
|---|
| Q1 2024 | TSHA
TAYSHA GENE THERAPIES INC | United States | COM SHS | 2,100,000 | 950,000 | -1,150,000 | $3,717,000 | $2,726,500 | -$990,500 | 2024-05-15 |
|---|
| Q1 2024 | ATXS
ASTRIA THERAPEUTICS INC | United States | COM | 335,000 | 115,000 | -220,000 | $2,572,800 | $1,618,625 | -$954,175 | 2024-05-15 |
|---|
| Q1 2024 | ARVN
ARVINAS INC | United States | COM | 59,250 | 40,000 | -19,250 | $2,438,730 | $1,651,200 | -$787,530 | 2024-05-15 |
|---|
| Q1 2024 | PTGX
PROTAGONIST THERAPEUTICS INC | United States | COM | 125,000 | 75,000 | -50,000 | $2,866,250 | $2,169,750 | -$696,500 | 2024-05-15 |
|---|
| Q1 2024 | NTRA
NATERA INC | United States | COM | 35,000 | 25,000 | -10,000 | $2,192,400 | $2,286,500 | +$94,100 | 2024-05-15 |
|---|
| Q3 2016 | CNMD
CONMED CORP | United States | COM | 175,000 | 45,000 | -130,000 | $8,353,000 | $1,803,000 | -$6,550,000 | 2016-11-14 |
|---|
| Q3 2016 | SRPT
SAREPTA THERAPEUTICS INC | United States | COM | 200,000 | 150,000 | -50,000 | $3,814,000 | $9,212,000 | +$5,398,000 | 2016-11-14 |
|---|
| Q3 2016 | BMRN
BIOMARIN PHARMACEUTICAL INC | United States | COM | 110,000 | 60,000 | -50,000 | $8,558,000 | $5,551,000 | -$3,007,000 | 2016-11-14 |
|---|
| Q3 2016 | BIIB
BIOGEN INC | United States | COM | 30,000 | 15,000 | -15,000 | $7,255,000 | $4,695,000 | -$2,560,000 | 2016-11-14 |
|---|
| Q2 2016 | BSX
BOSTON SCIENTIFIC CORP | United States | COM | 450,000 | 325,000 | -125,000 | $8,465,000 | $7,595,000 | -$870,000 | 2016-08-12 |
|---|
| Q1 2016 | ACAD
ACADIA PHARMACEUTICALS INC | United States | COM | 250,000 | 75,000 | -175,000 | $8,913,000 | $2,097,000 | -$6,816,000 | 2016-05-16 |
|---|
| Q1 2016 | IART
INTEGRA LIFESCIENCES HLDGS C | United States | COM NEW | 120,000 | 50,000 | -70,000 | $8,134,000 | $3,368,000 | -$4,766,000 | 2016-05-16 |
|---|
| Q1 2016 | PACB
PACIFIC BIOSCIENCES CALIF IN | United States | COM | 750,000 | 700,000 | -50,000 | $9,848,000 | $5,950,000 | -$3,898,000 | 2016-05-16 |
|---|
| Q1 2016 | VCYT
VERACYTE INC | United States | COM | 350,000 | 341,708 | -8,292 | $2,520,000 | $1,845,000 | -$675,000 | 2016-05-16 |
|---|
| Q4 2015 | PCRX
PACIRA PHARMACEUTICALS INC | United States | COM | 80,000 | 30,000 | -50,000 | $3,288,000 | $2,304,000 | -$984,000 | 2016-02-17 |
|---|
| Q3 2015 | ISRG
INTUITIVE SURGICAL INC | United States | COM NEW | 20,000 | 7,000 | -13,000 | $9,690,000 | $3,217,000 | -$6,473,000 | 2015-11-16 |
|---|
| Q3 2015 | NBIX
NEUROCRINE BIOSCIENCES INC | United States | COM | 122,500 | 55,000 | -67,500 | $5,851,000 | $2,188,000 | -$3,663,000 | 2015-11-16 |
|---|
| Q3 2015 | QURE
UNIQURE B.V. | | SHS | 185,000 | 150,000 | -35,000 | $4,995,000 | $3,068,000 | -$1,927,000 | 2015-11-16 |
|---|
| Q3 2015 | PBYI
PUMA BIOTECHNOLOGY INC | United States | COM | 17,500 | 6,500 | -11,000 | $2,043,000 | $490,000 | -$1,553,000 | 2015-11-16 |
|---|
| Q2 2015 | PBYI
PUMA BIOTECHNOLOGY INC | United States | COM | 30,000 | 17,500 | -12,500 | $7,083,000 | $2,043,000 | -$5,040,000 | 2015-09-09 |
|---|
| Q1 2015 | ALNY
ALNYLAM PHARMACEUTICALS INC | United States | COM | 55,000 | 40,000 | -15,000 | $5,335,000 | $4,177,000 | -$1,158,000 | 2015-05-15 |
|---|
| Q1 2015 | PTCT
PTC THERAPEUTICS INC | United States | COM | 85,000 | 60,000 | -25,000 | $4,400,000 | $3,651,000 | -$749,000 | 2015-05-15 |
|---|
| Q1 2015 | BMRN
BIOMARIN PHARMACEUTICAL INC | United States | COM | 40,000 | 35,000 | -5,000 | $3,616,000 | $4,362,000 | +$746,000 | 2015-05-15 |
|---|
| Q4 2014 | ISRG
INTUITIVE SURGICAL INC | United States | COM NEW | 8,500 | 4,000 | -4,500 | $3,925,000 | $2,116,000 | -$1,809,000 | 2015-02-18 |
|---|
| Q4 2014 | ATRC
ATRICURE INC | United States | COM | 250,000 | 100,000 | -150,000 | $3,680,000 | $1,996,000 | -$1,684,000 | 2015-02-18 |
|---|
| Q3 2014 | ALNY
ALNYLAM PHARMACEUTICALS INC | United States | COM | 75,000 | 35,000 | -40,000 | $4,738,000 | $2,734,000 | -$2,004,000 | 2014-11-14 |
|---|
| Q3 2014 | ENTA
ENANTA PHARMACEUTICALS INC | United States | COM | 50,000 | 35,000 | -15,000 | $2,154,000 | $1,385,000 | -$769,000 | 2014-11-14 |
|---|
| Q2 2014 | ARAY
ACCURAY INC | United States | COM | 400,018 | 250,000 | -150,018 | $3,840,000 | $2,200,000 | -$1,640,000 | 2014-08-14 |
|---|
| Q2 2014 | PBYI
PUMA BIOTECHNOLOGY INC | United States | COM | 11,330 | 1,000 | -10,330 | $1,180,000 | $66,000 | -$1,114,000 | 2014-08-14 |
|---|
| Q2 2014 | EW
EDWARDS LIFESCIENCES CORP | United States | COM | 30,000 | 20,000 | -10,000 | $2,225,000 | $1,717,000 | -$508,000 | 2014-08-14 |
|---|
| Q1 2014 | BIIB
BIOGEN IDEC INC | United States | COM | 16,000 | 6,471 | -9,529 | $4,473,000 | $1,979,000 | -$2,494,000 | 2014-05-15 |
|---|
| Q1 2014 | PBYI
PUMA BIOTECHNOLOGY INC | United States | COM | 25,000 | 11,330 | -13,670 | $2,588,000 | $1,180,000 | -$1,408,000 | 2014-05-15 |
|---|
| Q1 2014 | BMY
BRISTOL MYERS SQUIBB CO | United States | COM | 100,000 | 80,000 | -20,000 | $5,315,000 | $4,156,000 | -$1,159,000 | 2014-05-15 |
|---|
| Q1 2014 | INSM
INSMED INC | United States | COM PAR $.01 | 200,000 | 135,000 | -65,000 | $3,400,000 | $2,570,000 | -$830,000 | 2014-05-15 |
|---|
| Q1 2014 | PRTA
PROTHENA CORP PLC | Ireland | SHS | 130,000 | 110,000 | -20,000 | $3,448,000 | $4,214,000 | +$766,000 | 2014-05-15 |
|---|
| Q1 2014 | BRKR
BRUKER CORP | United States | COM | 115,000 | 90,000 | -25,000 | $2,274,000 | $2,051,000 | -$223,000 | 2014-05-15 |
|---|
| Q1 2014 | ARAY
ACCURAY INC | United States | COM | 450,000 | 400,018 | -49,982 | $3,915,000 | $3,840,000 | -$75,000 | 2014-05-15 |
|---|